Overview

Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH

Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
COVID-19 Infection has been found to cause endothelial dysfunction and most of the adverse events stem to this mechanism. So we seek to target endothelial dysfunction in critically Ill patients with covid by giving them an endothelial protocol ( L-arginine, Folic Acid, Statin, Nicorandil, Vitamin B complex) and monitor clinical outcome in those patients.
Phase:
Phase 3
Details
Lead Sponsor:
Lebanese American University Medical Center
Treatments:
Atorvastatin
Folic Acid
Nicorandil
Vitamin B Complex